New Hampshire Mesothelioma Information | Surviving Mesothelioma

New Hampshire

New Hampshire Mesothelioma Info

By clicking on the above tabs, you will find information on mesothelioma specific to the state of New Hampshire

New Hampshire Research and Clinical Trials

This is a partial list of scientific or medical grants in your state for research into mesothelioma and related illnesses.

New Hampshire Doctors and Hospitals

This is a partial list of hospitals and physicians that reportedly treat mesothelioma patients in your state.

New Hampshire Cases

This is a partial list of relevant court cases on mesothelioma in your state.

Disclaimer: Inclusion on this directory does not constitute endorsement by Cancer Monthly, Inc. All physicians who appear in this section do so based on their own expression of interest in the fields of mesothelioma treatment. Cancer Monthly, Inc. has not verified the competence, professional credentials, business practices or validity of the expressed interests of these physicians. Cancer Monthly makes no recommendation of any physician on this list and makes no suggestion that any such physician will cure or prevent any disease. Those consulting a physician on this list should approach the consultation exactly as they would with any other unknown physician.

Research

Abstract: Studies under this project have focused on the preparation of a number of hybridoma cell lines producing monoclonal anti-tumor cell antibodies and the use of these reagents to study the mechanism of antibody-sependent cell cytotoxicity (ADCC). We have now prepared three panels of monoclonal antibodies which are relatively specific for small cell carcinoma of the lung (SCCL), acute myelogenous leukemia (AML) or mesothelioma tumor cells. Using these reagents, we are now attempting to obtain new information useful in understanding ADCC and its importance. In particular, studies are being conducted to determine the effectiveness of various classes and subclasses of antibody, and the role of monocytes and isolated lymphocyte subpopulations in mediating ADCC. The possibility that ADCC reactions can be modulated has been explored. We have found that a number of physiological mediators including gamma-interferon are capable of dramatically enhancing ADCC by monocytes. This appears to result from induction of increased numbers of receptors for the Fc portion of immunoglobulins on these cells and perhaps on some increased activity of the monocytes’ cytotoxic capabilities. These findings have considerable therapeutic significance in that they imply that in vivo serotherapy with monoclonal antibody may be made significantly more efficacious by first inducing increased cytotoxic capabilities with gamma-interferon. We are also exploring other mediators as potential inducers of enhanced ADCC. It is anticipated that these studies should provide definitive information on some aspects of ADCC reactions and permit a better understanding of the role of this process in tumor immunity. Moreover, some of the information obtained may provide insights into in vivo approaches to the modulation of ADCC reactivity.

Tags: Allergy And Immunology Study Section, Cell Hybrids, Hybridomas, Immunity, Cellular, Cell Mediated Immune Responses, Antibody Dependent Cell Mediated Cytotoxicity, Immunological Preparations, Monoclonal Antibodies, Immunology, Antibody Formation, Immunology, Toxic Reactions And Mechanisms In Immunology Globulins, Gamma Globulins, Immunoglobulin(s), Immunology, Antigen-antibody Reactions, Immune Complexes, Immunology, Complement Receptors, Neoplasms Immunology Human Subjects, Volunteers, Human, Clinical, Mammals, Rodents, Myomorpha, Mice (laboratory), Tissue (cell) Culture

  • Followup Grant: 5R01CA031918-04
  • Followup Grant: 3R01CA031918-04S1

Abstract: The proposed role of the Cancer and Leukemia Group B (CALGB) as a research base for Community Clinical Oncology Programs (CCOPs) is described in this application. The CALGB has been funded for this activity for the last 6 years and during this time has organized the necessary committees, statistical input, data management, quality assurance procedures and educational activities required to support the treatment and cancer control research protocols mounted by the CALGB. Further development of the CALGB’s research base, as described in the application, will assist in broadening the CCOP program so as to better address the needs of medically underserved populations and the aged, and to enlarge the number and quality of cancer control research protocols.

Tags: Cancer Prevention, Cancer Rehabilitation /care, Community Health Service, Health Science Research Analysis /evaluation, Human Therapy Evaluation, Neoplasm /cancer Education, Neoplasm /cancer Therapy, Patient Care Planning Hodgkin’s Disease, Acute Leukemia, Acute Lymphoblastic Leukemia, Bladder Neoplasm, Bleomycin, Bone Marrow Transplantation, Breast Surgery, Cachexia, Cancer Information System, Cancer Registry /resource, Cancer Risk, Carmustine, Chronic Myelogenous Leukemia, Clinical Study /trial, Colony Stimulating Factor, Colorectal Neoplasm, Combination Chemotherapy, Continuing Education, Cooperative Study, Dacarbazine, Deoxycoformycin, Doxorubicin, Dyserythropoietic Anemia, Etoposide, Hairy T Cell Leukemia, Hydrazine, Interferon, Interleukin 2, Lymphocytic Leukemia, Mechlorethamine, Melanoma, Melphalan, Mesothelioma, Morphine, Multiple Myeloma, Neoplasm /cancer Chemotherapy, Neoplasm /cancer Diagnosis, Neoplasm /cancer Hormone Therapy, Neoplasm /cancer Immunotherapy, Neoplasm /cancer Radiation Therapy, Neoplasm /cancer Radionuclide Therapy, Neoplasm /cancer Surgery, Oat Cell Carcinoma, Oncogene, Prednisone, Procarbazine, Quality Of Life, Rural Area, Sarcoma, Self Medication, Smoking Cessation, Therapy Compliance, Vincristine Human Clinical Subject

Abstract: The proposed role of the Cancer and Leukemia Group B (CALGB) as a research base for Community Clinical Oncology Programs (CCOPs) is described in this application. The CALGB has been funded for this activity for the last 6 years and during this time has organized the necessary committees, statistical input, data management, quality assurance procedures and educational activities required to support the treatment and cancer control research protocols mounted by the CALGB. Further development of the CALGB’s research base, as described in the application, will assist in broadening the CCOP program so as to better address the needs of medically underserved populations and the aged, and to enlarge the number and quality of cancer control research protocols.

Tags: Cancer Rehabilitation /care, Community Health Service, Health Science Research Analysis /evaluation, Human Therapy Evaluation, Neoplasm /cancer Education, Neoplasm /cancer Therapy, Patient Care Planning Hodgkin’s Disease, Acute Leukemia, Acute Lymphoblastic Leukemia, Bladder Neoplasm, Bleomycin, Bone Marrow Transplantation, Breast Surgery, Cachexia, Cancer Information System, Cancer Registry /resource, Cancer Risk, Carmustine, Chemoprevention, Chronic Myelogenous Leukemia, Clinical Study /trial, Colony Stimulating Factor, Colorectal Neoplasm, Combination Chemotherapy, Continuing Education, Cooperative Study, Dacarbazine, Deoxycoformycin, Doxorubicin, Dyserythropoietic Anemia, Etoposide, Hairy T Cell Leukemia, Hydrazine, Interferon, Interleukin 2, Lymphocytic Leukemia, Mechlorethamine, Melanoma, Melphalan, Mesothelioma, Morphine, Multiple Myeloma, Neoplasm /cancer Chemotherapy, Neoplasm /cancer Diagnosis, Neoplasm /cancer Hormone Therapy, Neoplasm /cancer Immunotherapy, Neoplasm /cancer Radiation Therapy, Neoplasm /cancer Radionuclide Therapy, Neoplasm /cancer Surgery, Oat Cell Carcinoma, Oncogene, Prednisone, Procarbazine, Quality Of Life, Rural Area, Sarcoma, Self Medication, Smoking Cessation, Therapy Compliance, Vincristine Human Clinical Subject

  • Followup Grant: 5U10CA037447-10

Clinical Trials

Condition: Malignant Mesothelioma
Intervention: Drug: vatalanib
More Information

Condition: Malignant Mesothelioma
Intervention: Drug: gefitinib
More Information

Condition: Malignant Mesothelioma
Intervention: Drug: capecitabine
More Information

Condition: Ovarian; Melanoma; Renal; Prostate; Colorectal; Endometrial Carcinoma; Cervical Carcinoma; Testicular Cancer; Thyroid Cancer; Small Cell Lung Carcinoma; Mesothelioma; Breast Carcinoma; Esophageal Carcinoma; Gastric Cancer; Pancreatic Carcinoma; Neuroendocrine Cancer; Liver Cancer; Gallbladder Cancer; Biliary Tract Cancer; Anal Carcinoma; Bone Sarcomas; Soft Tissue Sarcomas; Carcinoma of Unknown Origin, Primary
Intervention: Biological: PSMA/PRAME
More Information

Condition: Tumor
Intervention: Drug: belinostat; Drug: 5-Fluorouracil (5-FU)
More Information

Condition: Cancer
Intervention: Other: biologic sample preservation procedure
More Information

Hospital and Cancer Centers

Norris Cotton Cancer Center
1 Medical Center Dr.
Lebanon, NH
603.650.5534

Cases

Lawyers

If you would like information on how to see the published ratings for different mesothelioma lawyers and law firms, please fill-in the form below:

Name (required)

State (required)

Your Email (required)

Phone

Get your free copy of
“Surviving Mesothelioma” Today!